BioAlliance ..Mein Bio-Topfavorit 2010 !
Seite 1 von 2 Neuester Beitrag: 25.04.21 01:38 | ||||
| Eröffnet am: | 18.03.10 10:37 | von: Biotechmaste. | Anzahl Beiträge: | 44 |
| Neuester Beitrag: | 25.04.21 01:38 | von: Susannekmc. | Leser gesamt: | 21.731 |
| Forum: | Hot-Stocks | Leser heute: | 4 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 > | ||||
Wer ein Solides Investment mit richtig viel Potential sucht der ist hier sehr gut aufgehoben .Macht eure Hausaufgaben und überzeugt euch selbt .
BioAlliance ( BIO.PA)
Marktkap: 65 Mio€
Cash: 14,7 €
Kurs: 5 €
Shares Out: 12,9 M
Pipeline
http://www.bioalliancepharma.com/var/plain_site/...tenu_editorial.jpg
Präsentation März 2010
http://www.bioalliancepharma.com/eng/content/...entation%20040310.pdf
The outlook for 2010
BioAlliance Pharma's forthcoming development milestones are as follows:
* Approval of the NDA for Loramyc® in the United States: Q2 2010.
* Approval of the marketing authorization application for Setofilm® in Europe: Q2 2010.
* An alliance in Europe for Loramyc® and Setofilm®: H1 2010.
* Meetings with the European and American regulatory agencies, in order to define the registration strategy for acyclovir Lauriad®: H1 2010.
* Market launch for Loramyc® in the United States: H2 2010.
* Continuation of ongoing clinical development throughout 2010.
Investoren
http://www.bioalliancepharma.com/var/plain_site/...tenu_editorial.jpg
http://www.bioalliancepharma.com/eng/content/...mptes%20S1%202010.pdf
25 August 2010
Consolidated accounts for the first semester of 2010: Significant revenues, Net profit for the first semester reflecting the contribution of licensing agreements, Strongly reinforced cash position
RT Chart
http://ih.advfn.com/...hart&s=EU%5EBIO&p=0&t=19&vol=1
EU und US Zulassungsantrag für Acyclovir in 2011 geplant . Die Partnerschaft(en) für das Produkt werden vorher abgeschlossen .
Acyclovir Lauriad®: US registration file submission planned end-2011
Paris, August 26th, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces that the US Food and Drug Administration (FDA) considers the positive results of the pivotal phase III study with acyclovir Lauriad® acceptable to submit a 505(b)(2) New Drug Application of the product in the United States.
Acyclovir Lauriad®, BioAlliance Pharma second product using the Lauriad® technology (Mucoadhesive Buccal Tablet), has been developed for the treatment of recurrent herpes labialis on the basis of one and only one tablet application as soon as the first signs of infection appear. As announced beginning of July, the European file submission is planned for mid-2011 based on the same clinical programme.
“This notification from the FDA confirms that acyclovir Lauriad® represents an innovation in the treatment of oro-facial herpes labialis and strengthens our position to find the adequate partner targeting dermatologists and general practitioners to successfully commercialize this opportunity”, declares Dominique Costantini, CEO of BioAlliance Pharma.
Neue Präsentation << Zeigt wie unterbewerte die Aktie ist
http://www.bioalliancepharma.com/eng/content/...%20260810%20Final.pdf
Präsentation << Hoffe das dieser link funktioniert !
http://www.bioalliancepharma.com/eng/...tions/Financial-presentations
Acyclovir ist der dritte kandidat und der game changer für Bioalliance das bald auf den Markt kommt . Die Phase 3-Studie wurde schon erfolgreich abgeschlossen .
Wir können uns schon bald auf Partnerschaft(en) für das Produkt freuen was natürlich weiter steigende kurse bedeutet ..
Acyclovir Lauriad®
Positive phase III final results giving significant competitive advantages: 775 patients included (EU, US, Australia)
Acyclovir Lauriad®, partnering opportunity
European registration file submission planned for Q2/Q3 2011
US registration file submission planned for Q3/Q4 2011
Target market:1 billion $ <<<<<<<<<<
07.09.2010 18:32
BioAlliance Pharma Announces the Grant of Its European Acyclovir Lauriad® Patent
Regulatory News:
BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent validation is a major step and the procedures up to the grant are ongoing in the other major global areas, America and Asia.
This patent specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing and its clinical application.
«Acyclovir Lauriad® enables a treatment of recurrent herpes labialis on the basis of one tablet application as soon as the first signs of infection appear. We are now looking for the adequate commercial partner for this innovation in the herpes labialis market. The agreement of the European and US Health Authorities, obtained this summer, to plan a registration dossier submission in 2011, together with the progress of our patents are obviously key steps in this process», stated Dominique Costantini, CEO of BioAlliance Pharma.
Intellectual Property constitutes a key asset of the Company and is at the heart of its R&D projects. BioAlliance's patent portfolio now comprises 34 families of published patents, including 358 patent applications and patents related to innovative technologies or products. Granted patents account for nearly 70% of this portfolio and provide BioAlliance Pharma's products with long term protection.
Bin kein Mediziner, muss nicht so kommen, kann aber wie immer ein failed werden. Werden wir mid 2017 sehen ...
Hier eine schöne Präsentation....demnach in Mitte 2017....also quasi jederzeit.
Wünsche uns Glück :-)